REKOMBINANTES PROTEIN

European patent · EP3630793 · In force

Register entry

Publication number
EP3630793
Application number
EP18726972
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 23, 2018
Published
Apr 8, 2020
Granted
Jul 10, 2024
Protection ends at the latest
May 22, 2038
Next annual fee due
May 31, 2027
IPC classes
C07K 7/08 (2006.01)
C07K 14/33 (2006.01)
C07K 14/315 (2006.01)
C07K 17/00 (2006.01)
C07K 1/16 (2006.01)
C07K 14/31 (2006.01)
C12N 15/62 (2006.01)
C07K 1/22 (2006.01)
C07K 16/00 (2006.01)
Priority
GB 201708277 24.05.2017
PCT application
PCT/EP2018/063435 23.05.2018
PCT publication
WO2018/215503 29.11.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. May 21, 2025

    Change

    Published in Swissreg on 21.05.2025

  4. Jul 15, 2024

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 15.07.2024

  5. Jul 10, 2024

    Granted

    Published in Swissreg on 10.07.2024

Parties

Holder

Cytiva BioProcess R&D AB

Björkgatan 30, 751 84 Uppsala, SE

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

GALLI, Joakim

751 84 Uppsala, SE

BJORKMAN, Tomas

751 84Uppsala, SE

BERGMAN, Magnus

751 84 Uppsala, SE

RODRIGO, Gustav

751 84 Uppsala, SE

ANDER, Mats

751 84 Uppsala, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.